nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—TLR4—age related macular degeneration	0.951	1	CbGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—SERPING1—age related macular degeneration	0.000209	0.00429	CbGpPWpGaD
Naloxone—CREB1—MyD88-independent cascade—TLR4—age related macular degeneration	0.000208	0.00426	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—RHO—age related macular degeneration	0.000207	0.00425	CbGpPWpGaD
Naloxone—CREB1—Toll Like Receptor 4 (TLR4) Cascade—CD36—age related macular degeneration	0.000203	0.00417	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—ELOVL4—age related macular degeneration	0.000201	0.00412	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—CFHR3—age related macular degeneration	0.000198	0.00405	CbGpPWpGaD
Naloxone—ALB—Binding and Uptake of Ligands by Scavenger Receptors—CD36—age related macular degeneration	0.000192	0.00395	CbGpPWpGaD
Naloxone—CREB1—Activated TLR4 signalling—TLR4—age related macular degeneration	0.000187	0.00383	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—RHO—age related macular degeneration	0.000187	0.00383	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—TGFBR1—age related macular degeneration	0.000185	0.00379	CbGpPWpGaD
Naloxone—CREB1—Toll-Like Receptors Cascades—CD36—age related macular degeneration	0.000181	0.00371	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—C2—age related macular degeneration	0.000176	0.00361	CbGpPWpGaD
Naloxone—CREB1—Toll Like Receptor 4 (TLR4) Cascade—TLR4—age related macular degeneration	0.000176	0.0036	CbGpPWpGaD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—ABCG4—age related macular degeneration	0.000172	0.00354	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—CST3—age related macular degeneration	0.00017	0.0035	CbGpPWpGaD
Naloxone—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—age related macular degeneration	0.00017	0.00348	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—CD36—age related macular degeneration	0.000168	0.00345	CbGpPWpGaD
Naloxone—CREB1—Oncostatin M Signaling Pathway—VEGFA—age related macular degeneration	0.00016	0.00329	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—C3—age related macular degeneration	0.000159	0.00327	CbGpPWpGaD
Naloxone—CREB1—HIF-1-alpha transcription factor network—VEGFA—age related macular degeneration	0.000158	0.00325	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—RHO—age related macular degeneration	0.000158	0.00324	CbGpPWpGaD
Naloxone—CREB1—Toll-Like Receptors Cascades—TLR4—age related macular degeneration	0.000156	0.00321	CbGpPWpGaD
Naloxone—ESR1—AP-1 transcription factor network—CCL2—age related macular degeneration	0.000154	0.00316	CbGpPWpGaD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—SLC16A8—age related macular degeneration	0.000154	0.00316	CbGpPWpGaD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—ABCA4—age related macular degeneration	0.000154	0.00316	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—SQSTM1—age related macular degeneration	0.000153	0.00315	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TGFBR1—age related macular degeneration	0.000153	0.00314	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—CRP—age related macular degeneration	0.000151	0.00311	CbGpPWpGaD
Naloxone—CREB1—Disease—RDH8—age related macular degeneration	0.000151	0.00309	CbGpPWpGaD
Naloxone—CREB1—Disease—NMNAT1—age related macular degeneration	0.000151	0.00309	CbGpPWpGaD
Naloxone—ALB—SLC-mediated transmembrane transport—SLC16A8—age related macular degeneration	0.000148	0.00303	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—CFH—age related macular degeneration	0.000147	0.00302	CbGpPWpGaD
Naloxone—TLR4—Immune System—SQSTM1—age related macular degeneration	0.000146	0.00299	CbGpPWpGaD
Naloxone—ALB—Vitamin B12 Metabolism—CRP—age related macular degeneration	0.000146	0.00299	CbGpPWpGaD
Naloxone—ALB—Lipid and lipoprotein metabolism—APOE—age related macular degeneration	0.000145	0.00297	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—CFB—age related macular degeneration	0.000143	0.00293	CbGpPWpGaD
Naloxone—CREB1—Immune System—C9—age related macular degeneration	0.000143	0.00293	CbGpPWpGaD
Naloxone—ALB—Vitamin B12 Metabolism—APOE—age related macular degeneration	0.000142	0.00292	CbGpPWpGaD
Naloxone—ESR1—Aryl Hydrocarbon Receptor—VEGFA—age related macular degeneration	0.000138	0.00284	CbGpPWpGaD
Naloxone—OPRD1—Peptide ligand-binding receptors—C3—age related macular degeneration	0.000135	0.00276	CbGpPWpGaD
Naloxone—CREB1—Disease—RPE65—age related macular degeneration	0.000132	0.0027	CbGpPWpGaD
Naloxone—CREB1—Immune System—CFI—age related macular degeneration	0.000124	0.00254	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—RHO—age related macular degeneration	0.00012	0.00247	CbGpPWpGaD
Naloxone—ALB—Vitamin B12 Metabolism—CCL2—age related macular degeneration	0.00012	0.00246	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—CRP—age related macular degeneration	0.000118	0.00243	CbGpPWpGaD
Naloxone—OPRK1—Peptide ligand-binding receptors—C3—age related macular degeneration	0.000118	0.00242	CbGpPWpGaD
Naloxone—CREB1—Immune System—CFHR3—age related macular degeneration	0.000115	0.00236	CbGpPWpGaD
Naloxone—ALB—Hemostasis—F13B—age related macular degeneration	0.000115	0.00235	CbGpPWpGaD
Naloxone—OPRD1—G alpha (i) signalling events—C3—age related macular degeneration	0.000114	0.00233	CbGpPWpGaD
Naloxone—ALB—Platelet degranulation—CD36—age related macular degeneration	0.000113	0.00231	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—RHO—age related macular degeneration	0.00011	0.00225	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—RHO—age related macular degeneration	0.000109	0.00224	CbGpPWpGaD
Naloxone—ALB—Hemostasis—SERPING1—age related macular degeneration	0.000108	0.00221	CbGpPWpGaD
Naloxone—ALB—Response to elevated platelet cytosolic Ca2+—CD36—age related macular degeneration	0.000107	0.0022	CbGpPWpGaD
Naloxone—CREB1—Disease—ABCA4—age related macular degeneration	0.000106	0.00218	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—RDH8—age related macular degeneration	0.000106	0.00217	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—RHO—age related macular degeneration	0.000105	0.00216	CbGpPWpGaD
Naloxone—OPRD1—Peptide ligand-binding receptors—CCL2—age related macular degeneration	0.000105	0.00216	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—RDH8—age related macular degeneration	0.000105	0.00216	CbGpPWpGaD
Naloxone—CREB1—Immune System—C2—age related macular degeneration	0.000103	0.0021	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—NMNAT1—age related macular degeneration	0.000102	0.0021	CbGpPWpGaD
Naloxone—OPRM1—Peptide ligand-binding receptors—C3—age related macular degeneration	9.98e-05	0.00205	CbGpPWpGaD
Naloxone—OPRK1—G alpha (i) signalling events—C3—age related macular degeneration	9.96e-05	0.00204	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—ELOVL4—age related macular degeneration	9.86e-05	0.00202	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—ELOVL4—age related macular degeneration	9.8e-05	0.00201	CbGpPWpGaD
Naloxone—TLR4—Immune System—CD36—age related macular degeneration	9.78e-05	0.00201	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—CCL2—age related macular degeneration	9.74e-05	0.002	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—RHO—age related macular degeneration	9.57e-05	0.00196	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—C3—age related macular degeneration	9.45e-05	0.00194	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—CRP—age related macular degeneration	9.41e-05	0.00193	CbGpPWpGaD
Naloxone—ALB—Hemostasis—RAD51B—age related macular degeneration	9.33e-05	0.00192	CbGpPWpGaD
Naloxone—TLR4—Immune System—C3—age related macular degeneration	9.27e-05	0.0019	CbGpPWpGaD
Naloxone—OPRK1—Peptide ligand-binding receptors—CCL2—age related macular degeneration	9.24e-05	0.0019	CbGpPWpGaD
Naloxone—CREB1—Disease—RHO—age related macular degeneration	9.24e-05	0.0019	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—RPE65—age related macular degeneration	9.23e-05	0.00189	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—RDH8—age related macular degeneration	9.23e-05	0.00189	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—RPE65—age related macular degeneration	9.2e-05	0.00189	CbGpPWpGaD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—C3—age related macular degeneration	9.03e-05	0.00185	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—age related macular degeneration	9.02e-05	0.00185	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—ELOVL4—age related macular degeneration	8.93e-05	0.00183	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—RHO—age related macular degeneration	8.91e-05	0.00183	CbGpPWpGaD
Naloxone—TLR4—Immune System—CRP—age related macular degeneration	8.82e-05	0.00181	CbGpPWpGaD
Naloxone—ALB—Hemostasis—SLC16A8—age related macular degeneration	8.68e-05	0.00178	CbGpPWpGaD
Naloxone—CREB1—Immune System—CFH—age related macular degeneration	8.58e-05	0.00176	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—ABCG4—age related macular degeneration	8.43e-05	0.00173	CbGpPWpGaD
Naloxone—OPRM1—G alpha (i) signalling events—C3—age related macular degeneration	8.42e-05	0.00173	CbGpPWpGaD
Naloxone—CREB1—Immune System—CFB—age related macular degeneration	8.32e-05	0.00171	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—LIPC—age related macular degeneration	8.28e-05	0.0017	CbGpPWpGaD
Naloxone—CREB1—Integrated Breast Cancer Pathway—VEGFA—age related macular degeneration	8.16e-05	0.00167	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFBR1—age related macular degeneration	8.1e-05	0.00166	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—RHO—age related macular degeneration	8.09e-05	0.00166	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—RPE65—age related macular degeneration	8.07e-05	0.00166	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—ERCC6—age related macular degeneration	8.06e-05	0.00165	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—KDR—age related macular degeneration	8.04e-05	0.00165	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—CETP—age related macular degeneration	7.99e-05	0.00164	CbGpPWpGaD
Naloxone—CREB1—SIDS Susceptibility Pathways—VEGFA—age related macular degeneration	7.95e-05	0.00163	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—C3—age related macular degeneration	7.92e-05	0.00163	CbGpPWpGaD
Naloxone—OPRM1—Peptide ligand-binding receptors—CCL2—age related macular degeneration	7.81e-05	0.0016	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RDH8—age related macular degeneration	7.8e-05	0.0016	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—CCL2—age related macular degeneration	7.74e-05	0.00159	CbGpPWpGaD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—CETP—age related macular degeneration	7.59e-05	0.00156	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—ABCA4—age related macular degeneration	7.51e-05	0.00154	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—SLC16A8—age related macular degeneration	7.51e-05	0.00154	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ABCA4—age related macular degeneration	7.44e-05	0.00153	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ABCA4—age related macular degeneration	7.41e-05	0.00152	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—ABCG4—age related macular degeneration	7.38e-05	0.00152	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—SLC16A8—age related macular degeneration	7.2e-05	0.00148	CbGpPWpGaD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL2—age related macular degeneration	7.07e-05	0.00145	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RDH8—age related macular degeneration	6.91e-05	0.00142	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—C3—age related macular degeneration	6.88e-05	0.00141	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RPE65—age related macular degeneration	6.82e-05	0.0014	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—VEGFA—age related macular degeneration	6.76e-05	0.00139	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—C3—age related macular degeneration	6.69e-05	0.00137	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—CD36—age related macular degeneration	6.64e-05	0.00136	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—ABCA4—age related macular degeneration	6.58e-05	0.00135	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—SLC16A8—age related macular degeneration	6.58e-05	0.00135	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ABCA4—age related macular degeneration	6.5e-05	0.00133	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—RHO—age related macular degeneration	6.47e-05	0.00133	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—RHO—age related macular degeneration	6.45e-05	0.00132	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL2—age related macular degeneration	6.2e-05	0.00127	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RPE65—age related macular degeneration	6.04e-05	0.00124	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—C3—age related macular degeneration	6.03e-05	0.00124	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—CD36—age related macular degeneration	5.86e-05	0.0012	CbGpPWpGaD
Naloxone—CREB1—Disease—CST3—age related macular degeneration	5.78e-05	0.00119	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—KDR—age related macular degeneration	5.74e-05	0.00118	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—RHO—age related macular degeneration	5.66e-05	0.00116	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CD36—age related macular degeneration	5.63e-05	0.00116	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—C3—age related macular degeneration	5.56e-05	0.00114	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ABCA4—age related macular degeneration	5.49e-05	0.00113	CbGpPWpGaD
Naloxone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—age related macular degeneration	5.48e-05	0.00112	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—CCL2—age related macular degeneration	5.38e-05	0.0011	CbGpPWpGaD
Naloxone—ALB—Platelet degranulation—VEGFA—age related macular degeneration	5.36e-05	0.0011	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—VEGFA—age related macular degeneration	5.34e-05	0.0011	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—C3—age related macular degeneration	5.33e-05	0.00109	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—CRP—age related macular degeneration	5.29e-05	0.00108	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL2—age related macular degeneration	5.24e-05	0.00108	CbGpPWpGaD
Naloxone—CREB1—Disease—TGFBR1—age related macular degeneration	5.19e-05	0.00106	CbGpPWpGaD
Naloxone—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—age related macular degeneration	5.11e-05	0.00105	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—C3—age related macular degeneration	5.1e-05	0.00105	CbGpPWpGaD
Naloxone—CREB1—Immune System—SQSTM1—age related macular degeneration	5.09e-05	0.00105	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—TLR4—age related macular degeneration	5.07e-05	0.00104	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NMNAT1—age related macular degeneration	5.02e-05	0.00103	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—CD36—age related macular degeneration	5e-05	0.00103	CbGpPWpGaD
Naloxone—ALB—Metabolism—NMNAT1—age related macular degeneration	4.99e-05	0.00102	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ABCA4—age related macular degeneration	4.87e-05	0.001	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—CD36—age related macular degeneration	4.8e-05	0.000985	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RHO—age related macular degeneration	4.78e-05	0.000981	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—VEGFA—age related macular degeneration	4.75e-05	0.000974	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—CCL2—age related macular degeneration	4.72e-05	0.000969	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—VEGFA—age related macular degeneration	4.43e-05	0.000909	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—age related macular degeneration	4.43e-05	0.000909	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ELOVL4—age related macular degeneration	4.39e-05	0.000901	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NMNAT1—age related macular degeneration	4.38e-05	0.000898	CbGpPWpGaD
Naloxone—ALB—Metabolism—ELOVL4—age related macular degeneration	4.36e-05	0.000896	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RHO—age related macular degeneration	4.24e-05	0.00087	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—age related macular degeneration	4.23e-05	0.000869	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—LIPC—age related macular degeneration	4.07e-05	0.000835	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—LIPC—age related macular degeneration	4.04e-05	0.00083	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—CCL2—age related macular degeneration	3.99e-05	0.000819	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—CETP—age related macular degeneration	3.92e-05	0.000805	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—CETP—age related macular degeneration	3.9e-05	0.000801	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—C3—age related macular degeneration	3.89e-05	0.000798	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ELOVL4—age related macular degeneration	3.82e-05	0.000785	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—CETP—age related macular degeneration	3.71e-05	0.000761	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—LIPC—age related macular degeneration	3.69e-05	0.000756	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TGFBR1—age related macular degeneration	3.63e-05	0.000745	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TGFBR1—age related macular degeneration	3.62e-05	0.000743	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CETP—age related macular degeneration	3.56e-05	0.00073	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—C3—age related macular degeneration	3.54e-05	0.000727	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—SLC16A8—age related macular degeneration	3.54e-05	0.000726	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—C3—age related macular degeneration	3.53e-05	0.000724	CbGpPWpGaD
Naloxone—ALB—Metabolism—SLC16A8—age related macular degeneration	3.52e-05	0.000722	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD36—age related macular degeneration	3.41e-05	0.000701	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—C3—age related macular degeneration	3.41e-05	0.0007	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SQSTM1—age related macular degeneration	3.29e-05	0.000676	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SQSTM1—age related macular degeneration	3.28e-05	0.000674	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—CETP—age related macular degeneration	3.25e-05	0.000667	CbGpPWpGaD
Naloxone—CREB1—Immune System—C3—age related macular degeneration	3.24e-05	0.000664	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TGFBR1—age related macular degeneration	3.18e-05	0.000652	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—VEGFA—age related macular degeneration	3.16e-05	0.000649	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—C3—age related macular degeneration	3.1e-05	0.000635	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—SLC16A8—age related macular degeneration	3.08e-05	0.000633	CbGpPWpGaD
Naloxone—CREB1—Immune System—CRP—age related macular degeneration	3.08e-05	0.000632	CbGpPWpGaD
Naloxone—CREB1—Immune System—TLR4—age related macular degeneration	2.95e-05	0.000606	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—C3—age related macular degeneration	2.88e-05	0.000591	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SQSTM1—age related macular degeneration	2.88e-05	0.000591	CbGpPWpGaD
Naloxone—CREB1—Disease—APOE—age related macular degeneration	2.78e-05	0.000571	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CCL2—age related macular degeneration	2.77e-05	0.000569	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CCL2—age related macular degeneration	2.76e-05	0.000567	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NMNAT1—age related macular degeneration	2.7e-05	0.000553	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TGFBR1—age related macular degeneration	2.68e-05	0.000551	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—C3—age related macular degeneration	2.62e-05	0.000537	CbGpPWpGaD
Naloxone—ALB—Hemostasis—CD36—age related macular degeneration	2.58e-05	0.000529	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SQSTM1—age related macular degeneration	2.43e-05	0.000499	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CCL2—age related macular degeneration	2.42e-05	0.000497	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—VEGFA—age related macular degeneration	2.38e-05	0.000488	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TGFBR1—age related macular degeneration	2.38e-05	0.000488	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—CD36—age related macular degeneration	2.36e-05	0.000484	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ELOVL4—age related macular degeneration	2.36e-05	0.000484	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—CD36—age related macular degeneration	2.34e-05	0.000481	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—age related macular degeneration	2.34e-05	0.000481	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SQSTM1—age related macular degeneration	2.16e-05	0.000443	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CD36—age related macular degeneration	2.14e-05	0.000439	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—C3—age related macular degeneration	2.09e-05	0.000429	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—C3—age related macular degeneration	2.09e-05	0.000428	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—APOE—age related macular degeneration	2.08e-05	0.000427	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—APOE—age related macular degeneration	2.07e-05	0.000425	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CCL2—age related macular degeneration	2.05e-05	0.00042	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—APOE—age related macular degeneration	1.95e-05	0.0004	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—APOE—age related macular degeneration	1.94e-05	0.000398	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KDR—age related macular degeneration	1.91e-05	0.000392	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KDR—age related macular degeneration	1.9e-05	0.00039	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC16A8—age related macular degeneration	1.9e-05	0.00039	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—APOE—age related macular degeneration	1.89e-05	0.000387	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—C3—age related macular degeneration	1.83e-05	0.000375	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—LIPC—age related macular degeneration	1.81e-05	0.000372	CbGpPWpGaD
Naloxone—ALB—Metabolism—LIPC—age related macular degeneration	1.8e-05	0.00037	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CETP—age related macular degeneration	1.75e-05	0.000359	CbGpPWpGaD
Naloxone—ALB—Metabolism—CETP—age related macular degeneration	1.74e-05	0.000357	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—APOE—age related macular degeneration	1.7e-05	0.000349	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KDR—age related macular degeneration	1.67e-05	0.000342	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCL2—age related macular degeneration	1.64e-05	0.000336	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCL2—age related macular degeneration	1.63e-05	0.000335	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—LIPC—age related macular degeneration	1.58e-05	0.000324	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—C3—age related macular degeneration	1.55e-05	0.000317	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CETP—age related macular degeneration	1.52e-05	0.000312	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—APOE—age related macular degeneration	1.44e-05	0.000295	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCL2—age related macular degeneration	1.43e-05	0.000294	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KDR—age related macular degeneration	1.41e-05	0.000289	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—C3—age related macular degeneration	1.37e-05	0.000281	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—APOE—age related macular degeneration	1.28e-05	0.000262	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KDR—age related macular degeneration	1.25e-05	0.000256	CbGpPWpGaD
Naloxone—ALB—Hemostasis—VEGFA—age related macular degeneration	1.23e-05	0.000252	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCL2—age related macular degeneration	1.21e-05	0.000248	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCL2—age related macular degeneration	1.07e-05	0.00022	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VEGFA—age related macular degeneration	1.05e-05	0.000216	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CD36—age related macular degeneration	1.05e-05	0.000216	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VEGFA—age related macular degeneration	1.05e-05	0.000215	CbGpPWpGaD
Naloxone—ALB—Metabolism—CD36—age related macular degeneration	1.04e-05	0.000214	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—LIPC—age related macular degeneration	9.72e-06	0.0002	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CETP—age related macular degeneration	9.38e-06	0.000192	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—APOE—age related macular degeneration	9.27e-06	0.00019	CbGpPWpGaD
Naloxone—ALB—Metabolism—APOE—age related macular degeneration	9.21e-06	0.000189	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VEGFA—age related macular degeneration	9.19e-06	0.000189	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CD36—age related macular degeneration	9.15e-06	0.000188	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—APOE—age related macular degeneration	8.07e-06	0.000166	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VEGFA—age related macular degeneration	7.77e-06	0.000159	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VEGFA—age related macular degeneration	6.89e-06	0.000141	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CD36—age related macular degeneration	5.64e-06	0.000116	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—APOE—age related macular degeneration	4.97e-06	0.000102	CbGpPWpGaD
